Compare · ARGX vs LXEO
ARGX vs LXEO
Side-by-side comparison of argenx SE (ARGX) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 145.0x LXEO ($368.3M).
- LXEO has been more active in the news (12 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- argenx SE
- Lexeo Therapeutics Inc.
- Price
- $861.30+0.30%
- $4.68+2.86%
- Market cap
- $53.41B
- $368.3M
- 1M return
- -
- -1.58%
- 1Y return
- -
- +13.32%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2023
- News (4w)
- 3
- 12
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest LXEO
- Chief Financial Officer Tamayo Louis Edward was granted 12,000 shares and sold $20,838 worth of shares (4,641 units at $4.49), increasing direct ownership by 8% to 97,024 units (SEC Form 4) to cover taxes
- Chief Operating Officer Otero Jose Manuel sold $20,904 worth of shares (4,666 units at $4.48) and was granted 12,060 shares, increasing direct ownership by 6% to 137,482 units (SEC Form 4) (withholding obligation)
- Chief Medical Officer Bhalla Narinder Pal was granted 55,000 shares and sold $98,593 worth of shares (22,306 units at $4.42), increasing direct ownership by 66% to 82,194 units (SEC Form 4) to cover withholding tax
- Chief Executive Officer Townsend Richard Nolan was granted 67,000 shares and sold $116,243 worth of shares (25,947 units at $4.48), increasing direct ownership by 12% to 377,817 units (SEC Form 4) to satisfy withholding tax
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Altschuler Steven
- SEC Form 4 filed by Director Agger Mette Kirstine
- SEC Form 4 filed by Director Cooperstone Brenda
- SEC Form 4 filed by Director Diaz Reinaldo M
- SEC Form 4 filed by Director Tanguler Tolga